PDGFRB and ovarian cancer: Further stratification, accounting for residual disease after surgery as strongest prognostic factor in ovarian cancer, showed that the prognostic value of stromal PDGFR-beta was confined to the subgroup of patients without residual disease after cytoreductive surgery.